ROCHE se defiende del acoso...(de Daniel?)

Since Pfizer’s move to acquire Wyeth at the beginning of the week, merger mania has reared its head again and Roche, with its attractive pipeline, was seen in some circles as a possible target. Novartis has a 33% stake in its fellow Swiss firm and in the past chief executive Daniel Vasella has spoken hypothetically about how strong a Roche/Novartis combination could be.

Mas...